News

Light-activated gold nanoparticles destroy potentially deadly bacterial cells in seconds.

Chemical compounds discovered which are able to attenuate the virulence of the bacterial human pathogen Listeria monocytogenes.

Commonly prescribed NSAIDs could be causing untold damage to patients.

GW Pharmaceuticals announces the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex® (cannabidiol or CBD) for the treatment of Dravet syndrome.

Company has announced partnership with Ctrl Group to develop first wearables for real-time cognitive health monitoring.

Technique may open doors to new treatments for many conditions, from cancer to autism.

Five-year collaboration encompasses up to 12 targets and provides up to $184 million in milestone payments per target.

Company has announced that the first patient has been treated with the Company’s cell therapy candidate for the blindness causing disease RP in a first-in-human US clinical trial.

Survey about product launch challenges finds instances of demand forecasts off by more than 50 percent, leading to sales losses and reputation damage.

The haploid stem cells may yield new genetic screening tools and therapies.